Muscle Loss: What Could Be Causing It?

What muscle loss means, and why the label matters

"Muscle loss," "muscle wasting," "sarcopenia," "cachexia," and "myopathy" get used interchangeably by patients, but they are not the same thing to a clinician. Sarcopenia is age-related decline in muscle mass and strength. Cachexia is an inflammatory, cytokine-driven wasting syndrome tied to chronic illness such as cancer, heart failure, or COPD, distinct from simple undereating. Myopathy means the muscle fiber itself is diseased, from causes as different as thyroid disease, statins, or autoimmune inflammation. Disuse atrophy is what follows immobilization of a limb or the whole body.

Muscle loss (also described as muscle wasting, and further classified as sarcopenia, cachexia, or myopathy depending on cause) has more than a dozen distinct underlying mechanisms with different tests and treatments. The most commonly missed reversible causes are hypogonadism, thyroid dysfunction, glucocorticoid excess, and inadequate protein intake, each identifiable from a single blood draw. Not every case is fully reversible: neurogenic atrophy from motor neuron disease and long-standing sarcopenia after age 70 typically respond only partially to treatment, and no single blood test or scan currently diagnoses both the presence and the cause of muscle loss in one step.

Why the wrong explanation is common

Patients and clinicians often default to "it's just aging" or "I'm not eating enough." That default fits some cases but misses others. Sarcopenia prevalence estimates in the geriatric literature vary widely by population and diagnostic criteria used, and a meaningful share of community-dwelling adults found to have low muscle mass turn out to have an identifiable secondary cause, such as hypogonadism or a thyroid disorder, that was never tested for. The exact proportion depends on the study and population, and specific percentages from older analyses should be verified against the current literature rather than treated as fixed facts.

The functional cost

Independent of its cause, low muscle mass is associated with worse surgical outcomes, higher fall and fracture risk, and higher all-cause mortality in observational studies. Health-system cost estimates for sarcopenia have been published, but the widely circulated figures are old and vary by methodology; a precise current dollar estimate is not something this article can support without checking the source data, so none is given here.

Evidence boundary: what is established, what is plausible, what is not

Established: Hypogonadism, uncontrolled thyroid disease, glucocorticoid excess, cancer and organ-failure cachexia, inflammatory myopathies, neurogenic atrophy, disuse, and inadequate protein intake are all recognized, guideline-documented causes of muscle loss with defined diagnostic criteria. Resistance training and adequate protein intake improve muscle mass and strength across nearly every cause studied. Testosterone replacement increases lean mass in men with confirmed hypogonadism.

Plausible but not settled for an individual reader: The exact rate of age-related muscle loss, the degree to which hormone therapy started early in menopause preserves muscle long-term, and the optimal protein target for a specific person with a specific illness are all active research areas with a range of published estimates rather than one settled number.

Not established: That any single supplement, over-the-counter hormone product, or single blood test can reliably diagnose the cause of muscle loss without a structured workup. Muscle loss is a symptom of many different diseases, and self-diagnosis based on one symptom or one lab value risks missing a serious underlying cause.

Cause 1: Normal aging (sarcopenia)

Age-related muscle loss typically becomes measurable starting in the 40s and accelerates after 60. The European Working Group on Sarcopenia in Older People (EWGSOP2) consensus defines sarcopenia as low muscle strength combined with low muscle quantity or quality, with a "severe" category when physical performance is also impaired. Its commonly cited screening cutoffs use grip strength and either DXA-derived or bioimpedance-derived lean mass, followed by a gait-speed or short physical performance battery test to confirm severity. Readers should confirm current numeric cutoffs with their clinician, since guideline thresholds are periodically revised.

Three overlapping mechanisms are generally described as driving age-related atrophy: declining anabolic hormones (testosterone, IGF-1, DHEA), low-grade chronic inflammation, and reduced capacity of satellite cells to regenerate muscle fiber. Because several of these are at least partly modifiable, sarcopenia is not treated as purely inevitable in current geriatric practice.

Cause 2: Hypogonadism and sex hormone deficiency

Low testosterone in men and estrogen deficiency in women are among the more commonly missed reversible causes of muscle loss in adults under 65, because testosterone directly stimulates muscle protein synthesis and estrogen supports satellite cell activation and repair.

Male hypogonadism. Endocrine Society guidance generally defines male hypogonadism using a low total testosterone confirmed on two morning measurements, with an accompanying symptom pattern. A large cardiovascular-safety trial of testosterone therapy in older men with hypogonadism (commonly referenced in the literature as the TRAVERSE trial) reported improvements in lean mass with testosterone therapy compared with placebo over roughly two years. Specific numeric effect sizes attributed to this trial in earlier drafts of this article could not be verified against a checked primary source and are omitted here; readers who want exact figures should ask their prescriber to pull the published trial data.

Female hormone deficiency. Muscle mass loss accelerates around menopause, plausibly linked to declining estradiol and reduced IGF-1 sensitivity. Some clinical reviews report that hormone therapy attenuates but does not fully prevent this loss, with a larger effect when started close to the final menstrual period. This is an area of active study rather than settled consensus, and hormone therapy carries its own risks and contraindications that must be weighed individually with a clinician, not decided from a symptom of muscle loss alone.

Cause 3: Cachexia from chronic disease

Cachexia differs from simple malnutrition. It is a cytokine-driven catabolic state in which muscle protein breaks down faster than it can be resynthesized, even when caloric intake looks adequate. Cancer, heart failure, COPD, chronic kidney disease, and HIV can each drive cachexia through overlapping inflammatory pathways.

Cancer cachexia. International consensus definitions generally require a combination of unintentional weight loss, low BMI, and reduced muscle index measured by imaging. Cancers of the pancreas and stomach are frequently cited as carrying especially high cachexia rates. Cachexia in the setting of cancer does not respond reliably to nutrition support alone if the underlying tumor and its inflammatory signaling are still active.

Cardiac and renal cachexia. A subset of patients with chronic heart failure develop cardiac cachexia, which observational studies associate with substantially worse survival compared with heart failure patients who do not lose lean mass. In chronic kidney disease, metabolic acidosis is thought to accelerate muscle protein breakdown, and correcting acidosis has been studied as a way to slow wasting in earlier-stage CKD; this is a treatment decision for a nephrologist, not something to attempt with over-the-counter bicarbonate.

Cause 4: Thyroid disorders

Both an underactive and an overactive thyroid can cause muscle loss, through opposite mechanisms. Hypothyroidism slows protein turnover and can produce a myopathy with proximal weakness and elevated creatine kinase. Hyperthyroidism accelerates protein breakdown faster than synthesis can compensate.

A TSH outside the normal reference range, confirmed with free T4, is generally sufficient to implicate the thyroid, and current thyroid society guidance supports checking TSH in anyone with unexplained proximal weakness. Muscle strength and mass generally improve over months once a euthyroid state is restored with treatment, though some patients, particularly those over 60, retain mild residual weakness. This recovery pattern is one way clinicians distinguish thyroid-related myopathy from primary muscle disease.

Cause 5: Glucocorticoid excess (Cushing syndrome or steroid myopathy)

Both prescribed corticosteroids and excess endogenous cortisol preferentially atrophy fast-twitch (type IIb) muscle fibers, and patients often notice proximal weakness before they notice visible muscle loss. Higher steroid doses sustained over weeks carry a clinically meaningful risk of steroid myopathy; the exact dose and duration threshold varies by patient and should be discussed with the prescribing clinician rather than assumed from a general rule.

Endogenous Cushing syndrome, from a pituitary adenoma, adrenal tumor, or ectopic ACTH source, is rare. Diagnosis relies on tests such as 24-hour urinary free cortisol, late-night salivary cortisol, or a low-dose dexamethasone suppression test, following guidance such as the Endocrine Society's Cushing's syndrome clinical practice guideline.

Muscle loss from exogenous steroids generally begins to reverse within weeks of dose reduction where the underlying condition allows it, and resistance training appears to blunt steroid-induced atrophy even when the steroid cannot be stopped.

Cause 6: Malnutrition and inadequate protein intake

Protein-energy malnutrition causes muscle loss through simple substrate deficiency: the body breaks down skeletal muscle to supply amino acids for gluconeogenesis and immune function during prolonged caloric restriction. This is also the mechanism suspected when aggressive very-low-calorie diets, including rapid weight-loss programs, produce disproportionate lean-mass loss alongside fat loss.

The RDA of 0.8 g protein/kg/day is a minimum intended to prevent deficiency, not a target optimized for preserving muscle during aging, illness, or intentional weight loss. Meta-analyses of resistance-training studies generally report that higher protein intake, up to a point, improves lean mass and strength gains beyond training alone, though the exact intake at which benefit plateaus varies across analyses and should not be treated as a fixed number.

GLP-1 receptor agonists and lean mass

GLP-1 receptor agonists such as semaglutide (marketed as Ozempic and Wegovy) produce substantial weight loss, and body-composition substudies of major semaglutide trials have reported that a meaningful minority of the weight lost is lean tissue rather than fat. Exact percentages vary between substudies and populations, and a specific number should be verified against the published substudy rather than quoted as universal. The practical implication that most obesity medicine guidance agrees on is that patients on GLP-1 therapy should prioritize adequate protein intake and resistance training to protect lean mass during rapid weight loss, as an off-label supportive measure rather than a labeled indication of the drug itself.

Cause 7: Inflammatory myopathies

Polymyositis, dermatomyositis, and inclusion body myositis are autoimmune conditions in which the immune system attacks muscle fibers directly. All three cause proximal weakness, but inclusion body myositis characteristically also involves distal hand and finger flexor weakness, which is atypical for the other two and is a useful clinical clue.

Diagnostic workup typically includes markedly elevated creatine kinase, autoantibody testing (such as ANA or myositis-specific antibodies), and MRI showing muscle edema, with classification criteria from rheumatology societies used to estimate probability. Muscle biopsy remains the diagnostic gold standard in ambiguous cases.

High-dose corticosteroids are generally first-line for polymyositis and dermatomyositis, with steroid-sparing immunosuppressants added early to limit long-term steroid exposure. Inclusion body myositis does not respond meaningfully to immunosuppression, which is itself a key diagnostic clue and a reason biopsy or expert rheumatology input matters before committing to a treatment course.

Cause 8: Neurological causes

Muscle is only as healthy as its nerve supply. Motor neuron diseases (ALS, spinal muscular atrophy), peripheral neuropathies (diabetic, hereditary), and nerve root compression from disc herniation all cause neurogenic atrophy. The pattern of weakness is often the first diagnostic clue: distal greater than proximal in peripheral neuropathy, asymmetric in radiculopathy, fasciculation-prominent in motor neuron disease.

Electromyography and nerve conduction studies differentiate myopathic patterns (small, polyphasic motor unit potentials) from neuropathic patterns (large, reinnervated units with reduced recruitment) with reasonable accuracy, and are generally recommended as the primary electrodiagnostic tool for unexplained weakness or atrophy.

Cause 9: Disuse atrophy

Muscle loss from immobilization begins within about a day of strict bed rest and continues at a meaningful daily rate the longer immobility lasts. Bed-rest studies in older adults have found that even a short period of strict bed rest can produce lean-mass loss comparable to what would otherwise take much longer through normal aging, which is why early mobilization after surgery or acute illness is treated as a genuine clinical priority, not a comfort measure.

Disuse atrophy is generally fully reversible with progressive loading, provided the nerve supply to the muscle is intact, though recovery typically takes longer than the period of immobilization itself.

How muscle loss gets worked up: a staged approach

No single test diagnoses muscle loss and identifies its cause at the same time. The following decision framework, developed for this article to help a reader understand what a reasonable workup sequence looks like, is a general staging tool, not a substitute for an individualized clinical evaluation.

Decision framework: matching your pattern to the next step

Tradeoff to understand: broad first-line lab testing (testosterone, TSH, cortisol, CRP, creatine kinase, CBC, metabolic panel) is inexpensive relative to imaging or biopsy and catches several reversible causes at once, but a normal panel does not rule out neurologic or early inflammatory disease, which need targeted testing (EMG, autoantibodies, biopsy) that a generalist panel will miss.

Exception to flag: in a person taking a GLP-1 medication or on an intentional very-low-calorie diet, some lean-mass loss is an expected part of weight loss, not automatically a sign of an independent disease. The distinguishing feature is proportion and rate: lean-mass loss that outpaces what would be expected from the amount of weight lost, or that continues after weight stabilizes, is what should prompt the fuller workup above.

Step 1: confirm the muscle loss is real

Grip strength testing or a DXA-derived lean mass measurement confirms that measurable muscle deficiency exists, separating it from subjective weakness without actual atrophy.

Step 2: screen for common reversible causes

A reasonable first-line panel includes total testosterone (drawn in the morning), TSH with free T4, cortisol, CRP or ESR, creatine kinase, CBC, a metabolic panel, albumin, and vitamin D. Cost varies by lab, insurance, and region; ask your lab or clinic for a specific estimate rather than relying on a fixed number.

Step 3: targeted follow-up testing

Markedly elevated creatine kinase generally prompts imaging of the affected muscle groups. An abnormal TSH prompts thyroid antibody testing. Elevated cortisol prompts confirmatory testing such as 24-hour urine cortisol. Suspected nerve involvement prompts EMG and nerve conduction studies through neurology.

Step 4: muscle biopsy

Biopsy is generally reserved for cases where an inflammatory myopathy panel is positive, where myopathy is suspected but the cause remains unclear after the earlier steps, or where inclusion body myositis is a real possibility.

What actually helps, by cause

Resistance training

Progressive resistance training is the single intervention with the broadest evidence base across essentially all causes of muscle loss, including sarcopenia. Systematic reviews of resistance training in older adults generally report meaningful improvements in strength and modest improvements in lean mass; exact effect sizes vary by review and population and should be checked against the specific review being cited rather than quoted as a universal number.

Protein and leucine-rich sources

Protein intake above the basic RDA, distributed across meals with attention to leucine-rich sources, is generally recommended by geriatric nutrition consensus groups for older adults and for those recovering from acute or chronic illness, with higher targets suggested during illness than in health. Specific gram-per-kilogram targets should be individualized with a clinician or dietitian, particularly for people with kidney disease, where high protein intake needs medical oversight.

Testosterone replacement therapy

For men with confirmed hypogonadism, testosterone replacement is associated with consistent lean-mass gains in clinical trials over roughly a year of treatment. Dosing, formulation, and monitoring (including hematocrit and prostate-specific antigen where relevant) must be individualized by a prescriber following current Endocrine Society guidance; this article does not provide dosing instructions, and starting testosterone without confirmed hypogonadism and medical supervision carries real risks.

Treating the underlying disease in cachexia

Cachexia generally does not respond reliably to nutrition support alone while the driving inflammatory process (an active tumor, decompensated heart failure, an COPD exacerbation) is still ongoing. Appetite stimulants and ghrelin-receptor agonists have been studied in cancer cachexia with mixed results on lean mass specifically, even when they improve appetite or weight; these are prescription decisions made with an oncologist or palliative care specialist, not something to pursue independently.

When to seek urgent care

Seek prompt medical evaluation, rather than watchful waiting, for any of the following: unintentional loss of 5% or more of body weight over six months, weakness that is progressing over days rather than months, difficulty swallowing, muscle twitching at rest, weakness affecting both legs, or a very high creatine kinase result. Conditions such as rhabdomyolysis, Guillain-Barre syndrome, and acute inflammatory myopathy can be serious if diagnosis is delayed, and none of them should be managed by waiting to see if symptoms improve on their own.

Current Endocrine Society guidance recommends testosterone testing in men presenting with signs or symptoms of testosterone deficiency, including decreased muscle mass and strength, as part of a broader symptom picture rather than muscle loss alone. In practice, testosterone testing is inconsistently ordered at first presentation, which is one reason a reversible cause of muscle loss can go unaddressed for longer than necessary; exact figures on how often this happens vary by dataset and should not be quoted as a fixed statistic.